TP53 codon 72 polymorphism in patients with chronic myeloid leukemia

被引：0

作者：

Bergamaschi, G ^{[1
]}

Merante, S

Orlandi, E

Galli, A

Bernasconi, P

Cazzola, M

机构：

[1] Policlin San Matteo, IRCCS, I-27100 Pavia, Italy

[2] Univ Pavia, Sch Med, Dept Internal Med, I-27100 Pavia, Italy

[3] Univ Pavia, Sch Med, Div Hematol, I-27100 Pavia, Italy

来源：

HAEMATOLOGICA | 2004年 / 89卷 / 07期

关键词：

chronic myeloid leukemia; imatinib mesylate; TP53; polymorphism;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：868 / 869

页数：2

共 10 条

[1] IS P53 POLYMORPHISM MAINTAINED BY NATURAL-SELECTION [J].

BECKMAN, G ;

BIRGANDER, R ;

SJALANDER, A ;

SAHA, N ;

HOLMBERG, PA ;

KIVELA, A ;

BECKMAN, L .

HUMAN HEREDITY, 1994, 44 (05) :266-270

[2] High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Grigg, A ;

Arthur, C ;

Taylor, K ;

Herrmann, R ;

Lynch, KP ;

Hughes, TP .

BLOOD, 2002, 99 (09) :3472-3475

[3]

CHU S, 2004, IN PRESS BLOOD

[4] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[5] The codon 72 polymorphic variants of p53 have markedly different apoptotic potential [J].

Dumont, P ;

Leu, JIJ ;

Della Pietra, AC ;

George, DL ;

Murphy, M .

NATURE GENETICS, 2003, 33 (03) :357-365

[6] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[7] Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia [J].

Kantarjian, HM ;

Talpaz, M ;

O'Brien, S ;

Giles, F ;

Garcia-Manero, G ;

Faderl, S ;

Thomas, D ;

Shan, JQ ;

Rios, MB ;

Cortes, J .

BLOOD, 2003, 101 (02) :473-475

[8]

Marktel S, 2003, HAEMATOLOGICA, V88, P260

[9] Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate [J].

O'Dwyer, ME ;

Mauro, MJ ;

Blasdel, C ;

Farnsworth, M ;

Kurilik, G ;

Hsieh, YC ;

Mori, M ;

Druker, BJ .

BLOOD, 2004, 103 (02) :451-455

[10]

Rosti G, 2003, HAEMATOLOGICA, V88, P256

← 1 →